Day: May 22, 2025

HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) — KBR (NYSE: KBR), a leader in human spaceflight expertise for more than 60 years, has signed a letter of intent with ACMI Properties to grow KBR’s commercial space capabilities including a human spaceflight food laboratory at NASA’s Exploration Park, adjacent to Johnson Space Center. The 45,000 square-foot, Houston-based facility would serve the growing commercial low-Earth orbit (LEO) industry where tailorable astronaut food systems and solutions will be designed, tested, validated, produced, and integrated into customer mission environments. “This KBR-led capability is expected to serve as a critical resource for NASA and its provider community by delivering safe, expertly developed food solutions tailored for human performance on spaceflight missions,” said Mark Kavanaugh, KBR President,...

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) — Imperial Metals Corporation (“Imperial” or the “Company”) (TSX:III) reports initial diamond drill results from the Mount Polley 2025 exploration program with a notable interval of 152.5 metres grading 0.46% copper and 0.97 g/t gold starting from a depth of 282.5 metres, including 85.0 metres grading 0.67% copper and 1.56 g/t gold starting at 285.0 metres in C2 Zone diamond drill hole C2-25-121. The C2 Zone is located immediately south of the Cariboo Pit and, similar to the Cariboo and the WX zones, gold values in the mineralization of the C2 Zone exceed copper values. Also, much of the copper mineralization near surface and along faults in this zone is oxidized which results in lower copper recovery in processing. Given the recent increase in gold price, exploration priority...

–  63% response rate observed among 43 evaluable patients –  79% overall survival rate at 12-months; 9 months median progression-free survival –  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Carla M. L. van Herpen M.D. Ph.D., Radboud University Medical Center, Nijmegen, Netherlands at the 2025 American Society...

– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd – – Encore presentation planned at EHA 2025 Congress – – Kura Oncology to host virtual investor event at 7:30pm ET / 4:30pm PT on June 2nd to discuss the trial results – SAN DIEGO and TOKYO, May 22, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced that an abstract highlighting the full data analyses from the KOMET-001 registration-directed trial of ziftomenib, a once-daily, oral investigational menin inhibitor, has been accepted for oral presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, IL from May 30 – June 3, 2025. The KOMET-001...

REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA). “The validation of our MAA represents the next significant milestone in our mission to deliver this important therapy to the broad PWS community, including those in the EU,” said Anish Bhatnagar, M.D., Chairman and Chief Executive Officer of Soleno Therapeutics. “Based on the data generated,...

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced five-year results from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi® (lifileucel). The C-144-01 trial investigated Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 and targeted therapy, where applicable. The five-year results included meaningful...

Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC – Median overall survival for CPS ≥20 is 39.3 months – Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC – Trial-in-progress currently enrolling patients Conference call on Friday, May 23 at 8:00 a.m. ET to discuss ASCO abstract data sets PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced publication of three Versamune® HPV abstracts now available on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. These abstracts...

ROUYN-NORANDA, Quebec, May 22, 2025 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB : ABMBF) announces its results for the third quarter ended March 31, 2025. All monetary values in this press release are expressed in Canadian dollars, unless otherwise indicated. Financial statements and management discussion and analysis are available on SEDAR+. Summary of financial results(In dollars) Three months endedMarch 31 Nine months endedMarch 31  2025   2024   2025   2024  Revenues –   –   –   255,000  Administration expenses 1,068,917   776,367   2,499,582   2,657,981  Care and maintenance 692,919   231,541   2,743,950   2,031,082  Exploration expenses 4,063,635   1,765,615   6,118,177   4,043,679  Settlement of litigation with Revenu Québec –   –   (1,452,757 ) –  Deferred...

LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (SEC) of the Company’s Registration Statement on Form S-1 (No. 333-286403), as amended, originally filed on April 4, 2025 (Registration Statement), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s common stock or any...

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois. An oral presentation will feature ALLO-316, an investigational AlloCAR T product targeting CD70. ALLO-316 is currently being studied in patients with advanced or metastatic renal cell carcinoma (RCC). Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors....